The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel

Abstract

Background: Clopidogrel activity is influenced by cytochrome P450 (CYP450). CYP2C19 polymorphisms vary by ethnicity and region. Objectives: To assess the effect of genetic polymorphisms in CYP2C19*2 and *3 and with clinical and demographic factors on major adverse cardiovascular events (MACE) in Kazak patients following percutaneous coronary intervention (PCI). Methods: We enrolled 397 patients with PCI treated with clopidogrel and aspirin for at least 12 months and recorded outcomes within 1 year. Approximately 2 mL of peripheral venous blood samples were used for genotype detection. Multivariable logistic regression analyses were performed to identify factors associated with MACE. Results: There were 95 patients (23.9%) who suffered MACE during the period. Logistic regression analysis revealed that CYP2C19*2 carriers (odds ratio [OR]: 2.431, 95% [confidence interval] CI: 1.136–5.275, P = 0.027) and poor metabolizers (OR: 2.128, 95% CI: 0.899–4.82, P = 0.043) were significantly associated with MACE. Conclusion: The CYP2C19*2 allele variants and poor metabolizers are associated with MACE in a clopidogrel-treated Kazak population with acute coronary syndrome following PCI.